New CRISPR-Cas9 Variants Improve Targeting Ability of Base Editors

May 20, 2019

|

NEW YORK (GenomeWeb) – A team led by researchers at the Broad Institute and the University of California, Berkeley has engineered new CRISPR-Cas9 variants that widen the targeting scope of base editors, thus broadening the number of human pathogenic variants that could potentially targeted.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

To Explain What They Mean

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

A Few Days

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

Slightly Larger Pool

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

Cell Studies Explore Microbiome Genes, Tumor Influence, More

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.

Featured White Papers

Automated Genomic DNA Extraction from Large Volume Whole Blood

RNAGEM - mRNA Profiles as Close to Biological Reality as Possible

Application Note: How to Pipette PCR Master Mix for Increased Accuracy in qPCR Results

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Aug

28

Featured Webinar

Beyond Cas9: CRISPR Gene Editing with Alternative Nucleases

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu